Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine.
Sjoerd H. van der Burg(Leiden University Medical Center), Cornelis J.M. Melief(ISA Pharmaceuticals (Netherlands)), Cornelis J.�H. van de Velde(Leiden University Medical Center), Rob A.�E.�M. Tollenaar(Leiden University Medical Center), Peter J.K. Kuppen(Leiden University Medical Center), Anke Redeker, Philippe Moingeon(Servier (France)), Marie-Claude Bonnet, Rienk Offringa(German Cancer Research Center), Anand G. Menon(Leiden University Medical Center), Jan W. Drijfhout(Leiden University)
PubMed
May 1, 2002
Cited by 91
Related Papers
Efficacy of MRI and Mammography for Breast-Cancer Screening in Women with a Familial or Genetic Predisposition
|New England Journal of Medicine|2004|1.7k
Definition and grading of anastomotic leakage following anterior resection of the rectum: A proposal by the International Study Group of Rectal Cancer
|Surgery|2009|1.5k
Genome-wide cell-free DNA fragmentation in patients with cancer
|Nature|2019|1.5k
Therapeutic cancer vaccines
|Journal of Clinical Investigation|2015|1.1k